H.Res. 928 — Affirming support for most-favored-Nation drug pricing for United States patients.

This section expresses the sense of the House of Representatives that (1) U.S. patients should not be charged more than patients in other countries for the same prescription drugs; (2) the United States is committed to reducing prescription drug costs for all U.S. citizens by supporting policies to align U.S. drug prices with those of other developed nations and other methods, including expanding Medicare drug price negotiation and promoting price competition; and (3) U.S. citizens should have access to high-quality, affordable prescription drugs.